On the recordSeptember 18, 2014
A combination of barriers, including, of course, the high cost of drug development and the small profit margins have helped to drive companies out of the anti-infectious space.
Source
congress.govEditor's note · Context
Barton discusses challenges in antibiotic drug development.
Share & report
More from Joe Barton
Apr 25, 2018
Mr. Administrator, you're not the first person to be the victim for lack of a better term, Washington politics.
Apr 25, 2018
Administrator Pruitt's ethical violations as the head of an Agency with a mission to protect the public's health demonstrate a concerning lack of integrity.
May 22, 2018
Mr. Speaker, the bill has already passed the House on a bipartisan vote. I think I am right that it passed with 261 votes the last time we sent it. The House bill is a little bit better bill than the Senate, but the Senate bill is better…
Apr 25, 2018
So do you deny now that fine particle pollution has these health impacts, and will these new regulations cause your Agency to disregard these sentinel studies?
Other voices in this conversation
